Close
RNS Number : 3486P
Alliance Pharma PLC
17 June 2022
 

For immediate release

17 June 2022

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Block Admission Application

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that it has applied for a block admission for a further 1,667,351 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM on 21 June 2022. This will be used to facilitate the admission of shares to trading following the exercise of options granted under the following two employee share schemes:

 

·      The Alliance Pharma plc Approved Share Option Plan 2005 (up to 167,351 shares);

·      The Alliance Pharma plc Long-Term Incentive Plan 2019 (up to 1,500,000 shares).

 

The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

 

New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.

 

At the time of this announcement, Alliance has 539,519,338 Ordinary Shares in issue.

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com




Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff


alliancepharma@buchanan.uk.com




Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith


Corporate Broking: James Black




Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams


Corporate Broking: Patrick Robb


 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, Alliance employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSBSGDLLUBDGDR